Most Recent
Mesoblast class action settlement wins court OK
A court has approved a $26.5 million settlement in a shareholder class action against regenerative medicine company Mesoblast.
IG Markets class action may drop conflicted remuneration claims
A class action against online trading platform IG Markets over alleged risky contracts for difference may drop its conflicted remuneration claims after struggling to find a sample group member.
AMP class action ‘in search of a case’ after four years, court told
AMP has won its bid for more information on a class action’s allegations that it charged excessive insurance premiums, saying the applicant appeared to be “in search of a case”.
Judge OKs cutting edge argument in $900M class action against CBA
A judge has allowed a class action against CBA and its former wealth management arm Colonial First State to add claims based on a novel theory of corporate responsibility that has implications for companies’ use of AI.
Real estate ‘mogul’ Sasha Hopkins slapped with $1.25M fine
A judge has ordered self-styled real estate mogul Sasha Hopkins to pay a $1.25 million penalty for luring investors to put their life savings into risky property developments. 
BHP says shareholders can’t expand class action because of ‘drafting error’
BHP has told an appeals court a shareholder class action should not be allowed to expand the group definition to correct an alleged drafting error.
REST’s reliance on law firms’ advice a winning defence in ASIC case
A judge has tossed ASIC's case against REST over alleged misleading representations, finding the representations were statements of opinion reasonably held based on the advice of lawyers.
Real estate ‘mogul’ Sasha Hopkins to cop $1.25M penalty in ASIC case
Self-described property 'mogul' Sasha Hopkins has agreed to pay a $1.25 million fine and face a four-year disqualification in proceedings by the corporate regulator.
Mesoblast reaches settlement in class action over COVID-19 treatment
Mesoblast has agreed to settle a shareholder class action centred on statements to the market about its Remestemcel-L treatment, resolving claims it misrepresented the efficacy of the therapy for COVID-19 patients.
Contingency fee ruling may face serious scrutiny in a High Court challenge, experts say
Although carefully reasoned, last week's landmark judgment by the Full Federal Court finding power to grant contingency fees to class action solicitors has placed the question of statutory authority to award settlement common fund orders on more unsteady ground than before, experts say.